Evidence map›Paper›PMID 41484619›Full record

ArticleMalaria journal2026

Moving towards high-dose primaquine or single-dose tafenoquine for Plasmodium vivax treatment in Cambodia: a meeting report from dissemination of results of the EFFORT trial to stakeholders.

Lek Dysoley, Sarah Cassidy-Seyoum, Bipin Adhikari, Aaryan Dahal, Nead Phoumen, Sin Srey, Touch Phalla, Prak Vonn, But Engrkruy, Oum Sovanarath and 43 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Malaria journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

53 authors.

Lek Dysoley *National Center for Parasitology, Entomology, and Malaria Control, Phnom Penh, Cambodia.
Sarah Cassidy-Seyoum *Global and Tropical Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, Australia.
Bipin AdhikariMahidol Oxford Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Aaryan DahalMahidol Oxford Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Nead PhoumenProvincial Health Department, Kampong Cham, Cambodia.
Sin SreyProvincial Health Department, Kampong Thom, Cambodia.
Touch PhallaProvincial Health Department, Kampong Thom, Cambodia.
Prak VonnProvincial Health Department, Kampong Chhnang, Cambodia.
But EngrkruyProvincial Health Department, Kampong Chhnang, Cambodia.
Oum SovanarathProvincial Health Department, Sisophon, Banteay Meanchey, Cambodia.
Hor MengkeaProvincial Health Department, Krong Ban Lung, Ratanakiri, Cambodia.
Pov RathanaProvincial Health Department, Preah Sihanouk, Cambodia.
Iv MakaraProvincial Health Department, Siem Reap, Cambodia.
Pen Kim HengProvincial Health Department, Senmonorom, Mondulkiri, Cambodia.
Yim HengProvincial Health Department, Kampot, Cambodia.
Huot KhlokProvincial Health Department, Samraong, Oddar Meanchey, Cambodia.
Khourn PongProvincial Health Department, Samraong, Oddar Meanchey, Cambodia.
Tov MoengProvincial Health Department, Koh Kong, Cambodia.
Sam VanthaProvincial Health Department, Koh Kong, Cambodia.
Ung SovietProvincial Health Department, Steung Treng, Cambodia.
Rin RavuthProvincial Health Department, Steung Treng, Cambodia.
Voeurng BunrethProvincial Health Department, Battambang, Cambodia.
Keo VannakProvincial Health Department, Kandaol Chrum, Tbong Khmum, Cambodia.
Ma SokhannProvincial Health Department, Kandaol Chrum, Tbong Khmum, Cambodia.
Ke KimmenProvincial Health Department, Pursat, Cambodia.
Khoy DyProvincial Health Department, Pursat, Cambodia.
Siv SamolProvincial Health Department, Doun Kaev, Takeo, Cambodia.
Koung LoProvincial Health Department, Preah Vihear, Cambodia.
Nuon SokuntheaProvincial Health Department, Preah Vihear, Cambodia.
Hok KryProvincial Health Department, Chbar Mon, Kampong Speu, Cambodia.
Ly KanhaProvincial Health Department, Chbar Mon, Kampong Speu, Cambodia.
Leng NarenProvincial Health Department, Kratie, Cambodia.
Sarith OumProvincial Health Department, Pailin, Cambodia.
Yok SovannProvincial Health Department, Pailin, Cambodia.
Ros ChannavuthProvincial Health Department, Prey Veng, Cambodia.
Chhun BunmengClinton Health Access Initiative, Phnom Penh, Cambodia.
Jayme HughesClinton Health Access Initiative, Phnom Penh, Cambodia.
Hannah BrindleClinton Health Access Initiative, Phnom Penh, Cambodia.
Yang HuClinton Health Access Initiative, Phnom Penh, Cambodia.
Sovann PengCatholic Services Relief, Phnom Penh, Cambodia.
Prum MardiUSAID Global Health Supply Chain Program-Procurement and Supply Management, Phnom Penh, Cambodia.
Im ChanryAbt Global, Phnom Penh, Cambodia.
Sodavuth PreapUNOPS, Phnom Penh, Cambodia.
Socheat HeoyUNOPS, Phnom Penh, Cambodia.
Farooq SabawoonUNOPS, Phnom Penh, Cambodia.
Thoang SokhaMalaria Consortium, Phnom Penh, Cambodia.
Pascal RingwaldWorld Health Organization, Mekong Malaria Elimination Programme, Phnom Penh, Cambodia.
Caroline A LynchMMV Medicines for Malaria Venture, Geneva, Switzerland.
Ric N PriceGlobal and Tropical Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, Australia.
Rupam TripuraMahidol Oxford Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Lorenz von SeidleinMahidol Oxford Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Angela DevineGlobal and Tropical Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, Australia.
Kamala ThriemerGlobal and Tropical Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, Australia. kamala.ley-thriemer@menzies.edu.au.

Funding

National Health and Medical Research Council 1182950World Health Organization 001
6 · The paper itself

Abstract

Cambodia has targeted malaria elimination by 2025. As the malaria burden has decreased in Cambodia, transmission has become more focal, and Plasmodium vivax has become the predominant species. The recurrent nature of P. vivax, due to its dormant liver stages causing relapses, is the main obstacle to malaria elimination in Cambodia. In 2021, Cambodia's National Center for Parasitology, Entomology and Malaria Control (CNM) rolled out low-dose 14-day primaquine (total dose 3.5 mg/kg) supported by point-of-care quantitative testing for glucose-6-phosphate dehydrogenase deficiency. However, this treatment is limited by poor adherence to its prolonged duration and suboptimal efficacy of the low total dose. The EFFORT clinical trial was conducted in four malaria-endemic countries, including Cambodia, to assess the safety and effectiveness of a 7-day unsupervised high-dose course of primaquine (7 mg/kg total dose) and single dose tafenoquine (300 mg) compared to 14-day unsupervised low-dose primaquine for the treatment of patients presenting with P. vivax malaria. In addition, data were collected on the feasibility and cost-effectiveness of these treatment options. CNM organized the national dissemination of the EFFORT study results on March 27, 2025, to inform key stakeholders and discuss the implications of the study findings for policy and practice in Cambodia.

Indexed as

AminoquinolinesAntimalarialsMalaria, VivaxPrimaquineAdolescentAdultCambodiaChildFemaleHumansMaleMiddle AgedPlasmodium vivaxYoung AdultAminoquinolinesAntimalarialsPrimaquinetafenoquineCambodiaMalariaPrimaquineRadical cureTafenoquineVivax

Identifiers

PMID41484619
PMCPMC12763851

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.